CareDx (CDNA) Stock: Buy, Sell, or Hold?
CDNA - CareDx, Inc.
$70.74
1.54 (2.23%)
▲
5d:
+9.35%
30d:
+25.23%
90d:
+88.09%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Oct 29, 2026
6d
Get Alerted When CDNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CDNA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CDNA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$42.84
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$26.60
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CDNA is currently trading at $70.74, which is considered extended relative to its 30-day fair value range of $56.50 to $67.60. From a valuation perspective, the stock is trading at a premium (Forward PE: 54.8) compared to its historical average (26.4). At these levels, the market is pricing in 27.6% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CDNA is in a strong uptrend. The price is approaching resistance at $72.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CDNA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDNA is in a strong uptrend. The price is approaching resistance at $72.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CDNA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$56.50 -
$67.60
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
16.7%
Protect Your Profits
Holding CDNA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($64.17)
- BEARISH: Market expects 27.6% growth - appears too optimistic based on history
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$56.50 -
$67.60
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$61.19
Resistance Level
$72.71
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
54.84
Wall Street Target
$64.17
(-9.3%)
Revenue Growth (YoY)
52.2%
Profit Margin
24.2%
Valuation Premium vs History
+27.6% premium
PE vs Historical
54.8 vs 26.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+27.6%
(market-implied from PE analysis)
1-Year Target
$90.26
(+28%)
2-Year Target
$115.18
(+63%)
3-Year Target
$146.97
(+108%)
3-Yr Target (if PE normalizes)
(PE: 55→26)
PE COMPRESSION
$70.75
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 54.8, Growth: 7.7%)
$88.25
(+25%)
Base:
(SPY PE: 19.9, Growth: 7.7%)
$31.96
(-55%)
Bear:
(PE: 16.9, Growth: 7.7%)
$27.17
(-62%)
📈
Valuation based on Current Earnings
Trailing PE: 33.27 | Current EPS (TTM): $2.08
Bull Case
$47.21
(-33%)
Analyst growth -38.0%, PE expands to 36.6
Base Case
$42.92
(-39%)
Market implied -38.0%, PE stable at 33.3
Bear Case
$47.06
(-34%)
Severe decline -20.0%, PE contracts to 28.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 21, 2026 8:58 PM ET
Data refreshes hourly during market hours. Next update: 9:58 PM
Data refreshes hourly during market hours. Next update: 9:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GH
Guardant Health Inc |
STRONG BUY
26 analysts |
$202 | 61 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
28 analysts |
$691 | 42 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$244 | 40 SELL |
|
NTRA
Natera Inc |
STRONG BUY
23 analysts |
$404 | 44 HOLD |
Advanced CDNA Option Strategies
Professional options setups generated by AI based on today's CDNA price and gamma walls.
